On May 13, China Pharmaceuticals announced that recently, Hainan General Sanyo, a wholly-owned subsidiary of the company, obtained three "Approval Notices for Supplementary Application of Drugs for Ceftazidime" approved and issued by the State Food and Drug Administration.
The drug passed the quality and efficacy of generic drugs.
It is understood that ceftazidime for injection belongs to the third-generation cephalosporin antibiotic.
It has high antibacterial activity against Enterobacteriaceae such as Escherichia coli and Pneumoniae bacteria, Haemophilus influenzae, Pseudomonas aeruginosa, etc.
It also has good antibacterial effect against nitrate-negative bacilli, Alcaligenes bacillus, etc.
It can be used for sensitive leather Sepsis, lower respiratory tract infections, abdominal and biliary tract infections, complicated urinary tract infections, and severe skin and soft tissue infections caused by Lanseria-negative bacilli.
Ceftazidime for injection was developed by GlaxoSmithKline.
It has been imported into the domestic market with a specification of 1.
0g, and the product name is Fudaxin/FORTUM.
(2) The State Food and Drug Administration will accept the application for consistency evaluation of the drug in May 2020.
(3) As of the disclosure date of this announcement, the investment in the research and development of the drug was approximately RMB 7.
66 million (unaudited).
(4) According to the website of the State Food and Drug Administration, as of the disclosure date of this announcement, 10 domestic manufacturers including General Sanyo have passed the consistency evaluation of the drug.
(5) According to the query data from Zhongkang, the domestic sales of ceftazidime for injection in 2020 will be approximately 2.
75 billion yuan.